EG329055 Inhibitors
EG329055 inhibitors are a class of chemical compounds that specifically target and inhibit the biological activity of a protein or molecular target associated with the EG329055 series. These inhibitors are characterized by their specificity and ability to modulate particular cellular pathways. The structure of these inhibitors generally includes aromatic rings, heterocyclic groups, and functional side chains that contribute to their binding affinity and selectivity. Their design is typically aimed at fitting into the binding pocket of their molecular target, resulting in a conformational change that impedes the normal function of the target molecule. This binding interaction is often stabilized through non-covalent forces such as hydrogen bonds, van der Waals interactions, and hydrophobic effects, which contribute to their inhibitory potency. As a result, EG329055 inhibitors are highly effective in modulating the activity of specific targets involved in various biological processes.
In terms of their physicochemical properties, EG329055 inhibitors exhibit a range of solubility, stability, and lipophilicity profiles, which can influence their behavior in biological systems. Their molecular weights, polarity, and charge states can vary depending on the specific design and functionalization of the inhibitor. These compounds are often optimized for high binding efficiency to their target proteins while minimizing off-target interactions that could lead to unintended biological effects. Additionally, the design of EG329055 inhibitors typically incorporates structural features that improve their metabolic stability and resistance to enzymatic degradation, allowing them to maintain their activity for a suitable duration within the system they are utilized in. Structural variations in EG329055 inhibitors enable a versatile approach to targeting different proteins or pathways, making this chemical class an important tool for studying the intricate mechanisms of molecular signaling and regulation within cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
Pan-lipase inhibitor affecting intracellular lipid metabolism. Orlistat directly inhibits lipases, including Lipo1, impacting lipid digestion in intracellular organelles. The inhibition of lipases leads to reduced intracellular lipid breakdown, influencing Lipo1 activity and highlighting its role in lipid metabolism within membrane-bounded organelles. | ||||||
Citilistat | 282526-98-1 | sc-358100 sc-358100A | 250 mg 1 g | $47.00 $104.00 | ||
Pan-lipase inhibitor modulating intracellular lipid metabolism. Cetilistat inhibits various lipases, including Lipo1, disrupting intracellular lipid breakdown processes crucial for organelle function. The direct inhibition of lipases sheds light on Lipo1's role in maintaining lipid homeostasis within membrane-bounded organelles. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic receptor agonist impacting lipolysis. Isoproterenol influences adrenergic signaling, indirectly affecting Lipo1 by modulating lipolytic processes crucial for intracellular lipid metabolism. The modulation of adrenergic signaling reveals the intricate interplay between signaling pathways and Lipo1 activity within membrane-bounded organelles. | ||||||
GW6471 | 880635-03-0 | sc-300779 | 5 mg | $295.00 | 9 | |
PPARα antagonist affecting lipid metabolism. GW6471 inhibits PPARα, indirectly influencing Lipo1 by disrupting PPARα-mediated regulation of lipid metabolism within intracellular organelles. The indirect inhibition of Lipo1 highlights the regulatory role of PPARα in lipid homeostasis within membrane-bounded organelles. | ||||||
Ethionamide | 536-33-4 | sc-211429 | 5 g | $250.00 | ||
DGAT1 inhibitor impacting lipid synthesis. E6005 inhibits DGAT1, indirectly influencing Lipo1 by disrupting lipid synthesis processes crucial for intracellular lipid metabolism. The indirect inhibition of Lipo1 underscores the interconnected pathways governing lipid homeostasis within membrane-bounded organelles. | ||||||
Exendin-4 | 141758-74-9 | sc-474611 sc-474611A | 500 µg 1 mg | $146.00 $198.00 | 1 | |
GLP-1 receptor agonist modulating insulin signaling. Exenatide indirectly affects Lipo1 by enhancing insulin signaling, influencing intracellular lipid metabolism. The modulation of insulin signaling reveals the intricate connection between hormonal regulation and Lipo1 activity within membrane-bounded organelles. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
PPARγ antagonist impacting lipid metabolism. GW9662 inhibits PPARγ, indirectly influencing Lipo1 by disrupting PPARγ-mediated regulation of lipid metabolism within intracellular organelles. The indirect inhibition of Lipo1 underscores the regulatory role of PPARγ in lipid homeostasis within membrane-bounded organelles. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AMPK activator affecting energy metabolism. AICAR indirectly influences Lipo1 by activating AMPK, modulating cellular energy homeostasis crucial for intracellular lipid metabolism. The indirect inhibition of Lipo1 highlights the intricate connection between cellular energy status and Lipo1 activity within membrane-bounded organelles. | ||||||
Atglistatin | 1469924-27-3 | sc-503147 | 5 mg | $330.00 | ||
Lipase inhibitor impacting intracellular lipid metabolism. Atglistatin directly inhibits lipases, including Lipo1, disrupting lipid breakdown processes crucial for organelle function. The direct inhibition of lipases provides insights into Lipo1's role in maintaining lipid homeostasis within membrane-bounded organelles. | ||||||
Imipramine | 50-49-7 | sc-507545 | 5 mg | $190.00 | ||
Tricyclic antidepressant affecting lipolysis. Imipramine indirectly influences Lipo1 by modulating adrenergic signaling and impacting lipolytic processes crucial for intracellular lipid metabolism. The modulation of adrenergic signaling reveals the intricate interplay between neurotransmitter pathways and Lipo1 activity within membrane-bounded organelles. | ||||||